Tapentadol
Viewing r1 — May 9, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
Tapentadol (3-[(2R,3R)-1-(dimethylamino)-2-methylpentan-3-yl]phenol) is a synthetic opioid of the phenylpropylamine class. It is structurally related to tramadol but operates without requiring metabolic activation. Tapentadol is a μ-opioid agonist and norepinephrine reuptake inhibitor, producing its effects through dual suppression of pain signaling — one opioid, one adrenergic.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
Developed by Grünenthal GmbH under the code CG5503 and first characterized in 2007,[2] tapentadol was approved by the US FDA in November 2008 — the first new centrally acting analgesic class in 25 years.[3][4] It is now a Schedule II controlled substance in the United States and carries equivalent restrictions in most major jurisdictions.
Subjective effects include analgesia, euphoria, sedation, and anxiolysis. The experience combines opioid warmth and pain erasure with a subtle noradrenergic alertness that makes tapentadol less somnolent than pure μ-opioid agonists at equivalent analgesic doses. Nausea, dizziness, and constipation are characteristic unsought effects, though gastrointestinal burden is lower than with equianalgesic oxycodone.[5]
Tapentadol produces physical dependence, and respiratory depression constitutes the primary lethal mechanism, with fatal blood concentrations documented at 1.0–3.2 mg/L.[6][7] Co-administration with CNS depressants markedly increases lethality; tolerance develops more slowly than with morphine but still narrows the safety margin over time.[2] The compound is well-characterized through Phase III trials, post-marketing surveillance spanning 8+ years, and extensive animal pharmacology.[8]
History[edit]
Discovery
Tapentadol was synthesized at Grünenthal GmbH in Aachen, Germany — the same laboratory that produced tramadol — as part of a medicinal chemistry program to combine opioid receptor agonism with monoamine reuptake inhibitor in a single molecule. The lead team, headed by T.M. Tzschentke, published the first pharmacological characterization in 2007, establishing the "μ-opioid-NRI" dual mechanism as a first-in-class profile.[2][1]
Clinical significance
The US FDA approved tapentadol immediate-release (marketed as Nucynta) in November 2008 for moderate-to-severe acute pain — the first new centrally acting analgesic class approved in 25 years.[3][4] Phase III trials demonstrated efficacy in postoperative pain, chronic low back pain, osteoarthritis, and diabetic neuropathy.[9][10] An extended-release formulation followed in 2011.[11]
Scheduling and modern context
In 2009 the US DEA placed tapentadol in Schedule II of the Controlled Substances Act — the same schedule as morphine and oxycodone — based on its μ-opioid mechanism rather than empirical abuse data.[12] Post-marketing surveillance has consistently shown lower abuse rates than all comparator Schedule II opioids,[8] yet the restrictive classification remains in every major jurisdiction.
The name tapentadol follows pharmaceutical generic naming conventions without disclosed etymological roots. Brand names vary by market: Nucynta (United States), Palexia (European Union, Australia), and Yantil (selected international markets). The compound occupies an unusual cultural position — marketed as a safer opioid alternative during the height of the opioid crisis, yet classified alongside the very drugs it was designed to improve upon.
Chemistry[edit]
Structural class
Tapentadol is a 3-substituted phenol derivative of the phenylpropylamine class. It shares structural lineage with tramadol — both carry a phenol moiety and a dimethylamino side chain — but tapentadol's scaffold is substantially simpler, lacking the cyclohexanol ring and methoxyl group that make tramadol dependent on CYP2D6 metabolic activation.[13]
The molecule consists of a phenol ring with a branched aliphatic chain at the 3-position containing an ethyl group, a methyl-substituted chirality carbon, and a terminal dimethylamino group.
Molecular identity
| Molecular formula | C₁₄H₂₃NO |
| Molecular weight | 221.34 g/mol |
Stereochemistry
Tapentadol contains two chiral centers, generating four possible stereoisomers. Only the (2R,3R) enantiomer carries analgesic activity; the (2S,3S) form is pharmacologically inactive at both the μ-opioid and the NET.[2] The pharmaceutical preparation uses the enantiomerically pure (2R,3R) form as the hydrochloride salt.
Physical properties
The pharmaceutical form is tapentadol hydrochloride. No published melting point or solubility data for the free base were identified in the indexed literature. The hydrochloride salt is formulated as immediate-release tablets (50, 75, 100 mg), extended-release tablets (50–250 mg), and an oral solution.[3][4]
Pharmacology[edit]
Mechanism of action
Tapentadol operates through a dual mechanism combining μ-opioid agonism and norepinephrine reuptake inhibitor within a single molecule — a profile designated "MOR-NRI".[1] These two actions are synergistic rather than simply additive: the noradrenergic component activates descending pain inhibition pathways that complement the ascending pain suppression mediated by opioid signaling.[2]
At the μ-opioid receptor, tapentadol acts as a full agonist with roughly 50-fold lower binding affinity than morphine — yet its in vivo analgesic potency is only 2–3-fold below morphine.[2] This disparity constitutes the primary evidence for synergistic dual-mechanism analgesia. In opioid receptor knockout mice, tapentadol retains partial pain-relieving activity attributable to the norepinephrine component alone.[14]
The norepinephrine reuptake inhibition increases synaptic norepinephrine availability, activating descending inhibitory pathways from the brainstem to the spinal cord. This mechanism is particularly relevant for neuropathic pain, where pure opioid analgesia is often insufficient.[15]
Tapentadol also weakly inhibits the SERT — substantially less than tramadol.[16][17] This residual serotonergic activity maintains a theoretical serotonin syndrome risk, though post-marketing surveillance over 8+ years has not confirmed the signal at standard doses.[14]
Pharmacokinetics
Oral bioavailability of the immediate-release formulation is approximately 32%, limited by extensive first-pass hepatic metabolism.[18][13] Peak plasma concentration occurs at approximately 1.25–1.5 hours after oral dosing.[18] The terminal half-life is approximately 4 hours for the IR formulation.[19][20]
A defining feature of tapentadol’s metabolism is its primary dependence on Phase II glucuronidation (UGT enzymes) rather than CYP450 oxidation.[18][13] This means genetic variations in CYP2D6 — which cause unpredictable efficacy with Tramadol — do not meaningfully alter tapentadol’s effects.[13][4]
Tapentadol forms no clinically relevant active metabolites. The major metabolite (tapentadol-O-glucuronide) is pharmacologically inactive.[21] Excretion is primarily renal, as conjugated metabolites.[18] Protein binding is low.[4]
Neuroscience[edit]
Where it acts
Tapentadol engages two distinct pain-modulatory circuits simultaneously. The opioid component activates the descending inhibitory pathway from the periaqueductal gray through the brainstem to the spinal cord, suppressing pain signals before they reach conscious awareness.[1] The norepinephrine component independently activates descending noradrenergic projections from the locus coeruleus to the spinal dorsal horn, providing a second layer of pain inhibition that operates without opioid receptor involvement.[2]
The mesolimbic mesolimbic pathway is activated by the opioid component, mediating euphoria and reinforcement — though animal data suggest tapentadol’s rewarding properties are attenuated relative to other opioids.[22]
Why it matters
The dual-mechanism design means less total opioid receptor activation is needed per unit of pain suppression. Because the noradrenergic component provides a non-opioid fraction of analgesia, tolerance develops approximately twice as slowly as with morphine in neuropathic pain models.[2] The nitric oxide signaling system modulates this tolerance: NOS inhibition reverses established tapentadol tolerance and attenuates withdrawal in animal models.[23]
Whether tapentadol exhibits biased agonism at the μ-opioid (preferring one intracellular signaling pathway over another) has not been investigated. A sigma-1 receptor interaction was identified[24] but its functional significance is unknown. No human neuroimaging studies examining tapentadol’s brain network effects have been published.
Subjective Effects[edit]
Tapentadol’s experiential character is shaped by the interplay of its two mechanisms: opioid warmth, pain suppression, and sedation overlaid with a subtle noradrenergic alertness that prevents the heavy somnolence typical of pure μ-agonists like morphine or oxycodone. At lower doses the alerting quality is more prominent; at higher doses the opioid sedation dominates. Set and setting modulate the experience less than with psychoactive compounds — the analgesic and mood effects are relatively consistent across contexts, though pain state significantly shapes the subjective character.
Relative to tramadol, tapentadol delivers more direct opioid character — greater analgesic depth, more pronounced euphoria — without the unpredictable efficacy that tramadol’s CYP2D6 dependence introduces. Compared with oxycodone or morphine, the analgesic and mood effects are qualitatively similar but carry measurably less constipation and nausea at equivalent pain-relieving doses.[5]
Effect Grid
Full therapeutic analgesia is achieved. Clear pain suppression dominates the experience, accompanied by noticeable sedation, warmth, and cognitive euphoria. Anxiety suppression becomes prominent. The dual-mechanism character is most apparent at this range — the experience is less purely somnolent than equianalgesic doses of morphine or oxycodone, with a subtle quality of wakefulness from the NRI component.
Nausea and dizziness emerge as common adverse effects (reported in ~24% and ~9% of trial participants, respectively). Pupil constriction is consistent. Constipation develops but at approximately 40% lower frequency than with equianalgesic oxycodone. Tactile euphoria manifests as a diffuse bodily warmth. Appetite suppression is mild.
Cognitive impairment (focus suppression, psychomotor slowing) is present but moderate. Driving and machinery operation are contraindicated during the active phase.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Tactile euphoria · Bodily heaviness · Constipation · Sedation · Spontaneous body sensations · Breathing alteration · Dizziness · Muscle relaxation · Nausea · Physical fatigue · Tingling / electric sensations · Appetite suppression · Dry mouth · Stimulation · Temperature dysregulation · Vomiting · Excessive sweating · Headache · Sexual arousal suppression · Vasoconstriction · Wakefulness · Abnormal heartbeat · Heart rate perception changes · Insomnia · Nasal congestion · Pain enhancement · Restlessness
Sedation · Spontaneous body sensations · Breathing alteration · Dizziness · Muscle relaxation · Nausea · Physical fatigue · Tingling / electric sensations · Appetite suppression · Dry mouth · Stimulation · Vomiting · Excessive sweating · Headache · Sexual arousal suppression · Vasoconstriction · Wakefulness · Abnormal heartbeat · Heart rate perception changes · Insomnia · Nasal congestion · Pain enhancement · Restlessness
Cognitive impairment · Focus suppression · Information processing suppression · Thought deceleration · Confusion · Language suppression · Memory suppression · Motivation suppression · Cognitive dysphoria · Thought disorganization · Delirium
Thought deceleration · Confusion · Language suppression · Memory suppression · Motivation suppression · Cognitive dysphoria · Thought disorganization
Anxiety · Dysphoria · Empathy suppression · Irritability
Disinhibition · Depersonalization · Derealization
Timeline
Initial absorption begins. A subtle warmth may be noticed as the compound enters systemic circulation. Analgesic effects are sub-threshold.
Analgesia builds progressively toward peak. Mood elevation and bodily warmth increase. The NRI alerting quality may become faintly perceptible against building opioid sedation.
Full analgesia, maximum euphoria, and sedation. The dual-mechanism character is most apparent — less purely somnolent than equianalgesic morphine. Nausea and dizziness are most likely during this phase.
Gradual decline of analgesia and subjective effects. Warmth fades. Mild physical fatigue and residual sedation develop.
Residual warmth and mild fatigue persist. Subtle mood effects may linger. Cognitive and psychomotor performance remain mildly impaired.
Safety[edit]
- Acute toxicity
- High
- Chronic toxicity
- Moderate
- Withdrawal
- Moderate
- Tolerance buildup
- moderate
- Tolerance reset
- 10 days
- Physical
- Moderate
- Psychological
- Moderate
- Compulsive redosing
- Low
- Dose escalation
- Moderate
- Cross-tol.
- opioids
Toxicity
Acute toxicity
No human LD₅₀ has been established. The primary mechanism of acute lethality is respiratory depression via μ-opioid agonism.[25][13] Fatal blood concentrations in forensic case reports range from 1.0–3.2 mg/L.[6][7] The first reported death involved intravenous injection with no other substances present;[6] other fatalities involved co-intoxication with opioids or sedatives.[7]
Co-administration with any CNS depressant — alcohol, benzodiazepines, other opioids — markedly increases the risk of fatal respiratory depression.[25]
Seizure risk
Tapentadol lowers the seizure threshold via its norepinephrine reuptake inhibitor component.[14] This is a class effect shared with other NRI compounds and is the basis for contraindication in people with seizure disorders.
Organ toxicity
No specific organ toxicity beyond opioid class effects has been documented. Severe liver impairment increases bioavailability unpredictably due to reduced glucuronidation capacity.[18] Safety in severe liver or kidney impairment has not been established.
Psychological risks
Tapentadol produces opioid-characteristic euphoria, which constitutes the primary psychological reinforcement pathway. Cognitive impairment (sedation, dizziness, impaired attention) occurs at therapeutic doses. Mood disturbance — dysphoria, irritability, anxiety — emerges during dose reduction and withdrawal.
Drug-seeking behavior and dose escalation may develop with chronic use, though post-marketing surveillance indicates these occur at lower rates than with comparator Schedule II opioids.[8] No tapentadol-specific psychiatric effects distinct from opioid class effects have been documented.
Tolerance and dependence
Tolerance to tapentadol’s analgesic effects develops with chronic use but at approximately half the rate of morphine tolerance in neuropathic pain models.[2][23] The slower development is attributed to the non-opioid fraction of analgesia: because the norepinephrine component does not produce opioid-type tolerance, less total receptor desensitization occurs per unit of pain suppression.
Physical dependence develops with prolonged use. Abrupt discontinuation produces opioid withdrawal syndrome. Gradual tapering is recommended for discontinuation.[26]
US post-marketing surveillance (RADARS system) demonstrated that tapentadol abuse rates were significantly lower than all other opioids examined, including tramadol, hydrocodone, morphine, and oxycodone.[8][27] Animal studies show tapentadol induces short-term reward but does not retain this preference over days, suggesting lower craving incubation than tramadol.[22]
Drug interactions
CNS and respiratory depression
Combination with any CNS depressant — alcohol, benzodiazepines, barbiturates, other opioids, GHB/GBL — produces additive respiratory and central nervous system depression with potentially lethal consequences.[13][25] Alcohol is specifically documented as a lethal interaction.
Serotonergic interactions
MAOIs are contraindicated with a mandatory 14-day washout period.[18][4] Combination with SSRIs, SNRIs, tricyclic antidepressants, linezolid, or methylene blue increases serotonin syndrome risk.[16][17] Post-marketing data have not confirmed serotonin syndrome at standard doses,[14] but case reports document it in overdose.[28]
Pharmacokinetic interactions
Because tapentadol is metabolized by UGT enzymes (not CYP450), standard CYP-based drug interaction concerns are largely inapplicable. However, UGT inhibitors can markedly increase tapentadol levels — sorafenib co-administration increased peak concentration 5.3-fold in an animal model.[18] Valproic acid and probenecid are potential UGT inhibitors of concern.
Naloxone response
Tapentadol overdose is partially reversed by naloxone. Standard naloxone protocols for opioid overdose apply. The norepinephrine component of toxicity — particularly cardiovascular effects — may not be fully reversed by naloxone alone.citation needed
Contraindications
- MAOI use within 14 days: Absolute contraindication due to risk of serotonergic and adrenergic crisis.[18][4]
- Concurrent CNS depressants: Enhanced respiratory depression; combination with alcohol, benzodiazepines, or other opioids carries lethal risk.[13]
- Seizure disorders: Tapentadol lowers the seizure threshold. Contraindicated in epilepsy.[14]
- Severe liver impairment: Reduced glucuronidation increases bioavailability unpredictably.[18]
- Severe kidney impairment: Safety not established.[18]
- Pregnancy and nursing: Neonatal opioid withdrawal syndrome is a risk with chronic maternal use.[18]
- Children under 18: Standard tablet formulations not established for pediatric use.[29]
Harm Reduction[edit]
Forms & Identification
Tapentadol circulates almost exclusively as pharmaceutical tablets in blister packs or pharmacy bottles. Unlike many opioids, large-scale illicit manufacture has not been documented — diversion of prescribed supply is the primary source of non-medical use. This means product identity is usually verifiable via pill imprint codes and manufacturer markings.
The key risk is not adulteration but formulation confusion: extended-release tablets contain far higher total doses than immediate-release tablets. Crushing, splitting, or dissolving an ER tablet defeats the release mechanism and delivers the full dose at once. Verify the formulation type (IR vs. ER) before any use.
Guidelines
- Start at the lowest available dose if opioid-naïve. Tapentadol’s dual mechanism means effective analgesia occurs at doses that would appear low for a pure opioid.
- Do not combine with alcohol, benzodiazepines, other opioids, or any sedating substance.
- Do not crush or split extended-release tablets under any circumstances.
- Wait the full onset period (30–60 minutes) before considering redosing. The noradrenergic alertness can mask the degree of opioid intoxication.
- Do not use alone. If using alone is unavoidable, inform someone of the dose and time, and arrange a check-in.
- Keep naloxone accessible whenever using any opioid.
Set & Setting
Opioid effects are less context-sensitive than psychedelics, but environment still matters for safety. Use in a location where falling asleep is safe — not driving, not in water, not standing at height. The sedative onset can be rapid once the dose takes hold.
Have a trusted person present who knows what was taken, how much, and when. This person should know the signs of respiratory depression and have access to naloxone.
Aftercare & integration. After acute opioid effects resolve, allow 24 hours before driving or operating machinery — residual cognitive impairment outlasts subjective awareness of intoxication. Hydrate adequately and eat when appetite returns; opioid-induced nausea often suppresses food intake.
If using tapentadol for chronic pain management, track analgesic efficacy honestly over time. Escalating doses to maintain the same relief is the earliest signal of tolerance development. Discuss this with a prescriber before self-adjusting.
If the use was non-medical, honest self-assessment is warranted: how frequently is the impulse to use arising, and is it tied to pain suppression or to the mood effects? The distinction matters for understanding personal risk trajectory.
Recovery & Support
Tapentadol withdrawal is physically uncomfortable but not typically life-threatening. Symptoms include muscle aches, restlessness, insomnia, diarrhea, sweating, and anxiety. Gradual dose reduction under medical supervision minimizes withdrawal severity.[26]
For people seeking to discontinue chronic use, options include medically supervised tapering, transition to buprenorphine maintenance, or residential treatment programs. The lower abuse liability relative to other Schedule II opioids does not eliminate dependence risk — physical dependence develops with any regular opioid use regardless of the compound’s abuse potential in population data.
Support resources include SAMHSA’s National Helpline (US: 1-800-662-4357), local addiction medicine services, and peer support groups familiar with opioid recovery.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency: Slow or stopped breathing (fewer than 8 breaths per minute), blue or grey lips and fingertips, gurgling or snoring sounds while unconscious, unresponsiveness to voice or pain stimulation. The noradrenergic component may maintain a higher heart rate than typical opioid overdose, making breathing rate the most reliable indicator.
Immediate steps:
- 1. Call emergency services immediately.
- 2. Administer naloxone if available (intranasal or intramuscular). Repeat every 2–3 minutes if no response.
- 3. Place the person in the recovery position (on their side) to prevent aspiration.
- 4. Perform rescue breathing if trained and breathing has stopped.
- 5. Do NOT leave the person alone. Do NOT induce vomiting.
What to tell the dispatcher: Name the substance (tapentadol/Nucynta/Palexia), the approximate amount, when it was taken, and current symptoms. Mention any other substances involved. Good Samaritan laws in many jurisdictions protect people who call for help during an overdose.
Reversal agent: Naloxone reverses the opioid component of tapentadol toxicity. Standard opioid overdose naloxone dosing applies. Be aware that cardiovascular effects from the norepinephrine component may persist after naloxone administration.
Legal Status[edit]
Tapentadol is classified as a controlled substance in all major jurisdictions, reflecting its μ-opioid agonist activity. The compound was placed in the most restrictive prescription-opioid schedules despite post-marketing evidence of lower abuse rates than comparator Schedule II opioids — a regulatory posture driven by precautionary classification based on mechanism rather than empirical abuse data.[8]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule II (Controlled Substances Act) | Placed by DEA in 2009; covers all isomers, esters, ethers, and salts[12] |
| United Kingdom | Class A / Schedule 2 (Misuse of Drugs Act 1971) | Added via SI 2011/744 effective 28 March 2011; classified alongside morphine and hydromorphone[30] |
| European Union | National control (varies by member state) | EMA approved Palexia in 2010; individual member state scheduling applies[31] |
| Canada | Schedule I (CDSA) / Narcotic Control Regulations | Added in July 2015 via Canada Gazette[32] |
| Australia | Schedule 8 (controlled drug) | TGA-approved as Palexia; prescription opioid controls apply[33] |
The US DEA’s Schedule II placement — the same schedule as morphine, oxycodone, and fentanyl — was based on tapentadol’s opioid mechanism and structural classification rather than empirical abuse rate data, which consistently show lower abuse event rates than all comparator opioids in population-level surveillance.[8][27]
No structural analog act considerations apply, as tapentadol is specifically scheduled in all major jurisdictions.
references
- [1] ^abcdTzschentke TM, Christoph T, Kögel BY (2014) The mu-opioid receptor agonist/noradrenaline reuptake inhibition (MOR-NRI) concept in analgesia: the case of tapentadol — CNS Drugs doi:10.1007/s40263-014-0151-9
- [2] ^abcdefghiTzschentke TM, Christoph T, Kögel B, Schiene K, Hennies HH, Englberger W, Haurand M, Jahnel U, Cremers TI, Friderichs E, De Vry J (2007) (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties — Journal of Pharmacology and Experimental Therapeutics PMID:17656655
- [3] ^abcWade WE, Spruill WJ (2009) Tapentadol hydrochloride: a centrally acting oral analgesic — Clinical Therapeutics doi:10.1016/j.clinthera.2009.12.003
- [4]
- [5] ^abHartrick C, Van Hove I, Stegmann JU, Oh C, Upmalis D (2009) Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease — Clinical Therapeutics doi:10.1016/j.clinthera.2009.02.009
- [6] ^abcKemp W, Schlueter S, Smalley E (2013) Death due to apparent intravenous injection of tapentadol — Journal of Forensic Sciences doi:10.1111/j.1556-4029.2012.02299.x